A number of equities research analysts have issued reports on the company. Berenberg Bank decreased their price objective on GSK from GBX 1,820 ($23.52) to GBX 1,600 ($20.68) and set a “buy ...

GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more promising than they seem. To properly understand GSK's profit results ...

LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

One of the lowest paid CEOs in pharma—and one of the only woman leading a top-tier giant—is set to receive up to $27.2 ...

GSK’s pentavalent option comes well after vaccine rival Pfizer and its Penbraya hit the market in 2023. That shot similarly mixes components from the company’s other meningococcal vaccines ...

Accordingly, GSK investors that purchase the stock on or after the 20th of February will not receive the dividend, which will be paid on the 10th of April. The company's next dividend payment will ...

Tony Wood, GSK’s chief scientific officer, acknowledged it might be easier to communicate the company’s potential if he could point to “one big drug”, but said: “It is in some ways an ...

combines the immune response-generating components of two of the company's approved vaccines, Bexsero and Menveo, to protect against the five most common strains of meningococcal bacteria, GSK ...

GSK plc announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval of Ziihera® (zanidatamab-hrii), a treatment for advanced HER2-positive biliary tract cancer in adults who have ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against five meningococcal serogroups, the company announced. The vaccine ...